Swiss pharmaceutical giant Roche has entered into a licensing agreement worth up to $1.16 billion with Chinese biotech firm Rona Therapeutics to develop an investigational obesity drug candidate, live reported on October 13, 2026. The transaction marks Roche’s latest move to challenge established market leaders Eli Lilly and Novo Nordisk in the rapidly growing global obesity therapeutics sector.
Upfront Payments and Financial Milestones Structured in the Agreement
Under the terms of the accord, Rona Therapeutics will collect an immediate upfront payment of $100 million. The Chinese biotech firm also qualifies for up to $1.06 billion in subsequent development, regulatory, and commercial milestone payments, alongside tiered royalties on future global net sales, according to Rona Therapeutics. Boris L. Zaïtra, Head of Corporate Business Development at Roche, stated that the partnership complements the company’s cardiovascular, renal, and metabolism pipeline and reinforces its commitment to next-generation metabolic therapies.
ALK7 Targeting and Extrahepatic Delivery Technology
The licensed asset is an investigational RNA interference candidate that targets activin receptor-like kinase 7, which is encoded by the ACVR1C gene and predominantly expressed in adipose tissue, Rona Therapeutics stated. Stella Shi, CEO and Founder of Rona Therapeutics, explained that inhibiting ALK7 by directly targeting adipocytes offers a differentiated approach that could selectively reduce visceral and ectopic fat depots while preserving lean muscle mass. This mechanism is designed to operate as a complementary treatment alongside existing incretin-based therapies.
Pipeline Context and Prior Mid-Stage Clinical Data
The agreement builds on Roche’s broader clinical expansion into metabolic disorders. In September, the Swiss drugmaker reported positive mid-stage data for enicepatide, its separate candidate for obesity and diabetes, which demonstrated the ability to help patients lose weight and lower blood sugar levels, live reported. Rona Therapeutics, established in 2021, continues to advance multiple programs through its proprietary platform for extrahepatic delivery and multi-valency oligonucleotide chemistry.
Frequently Asked Questions About the Roche and Rona Therapeutics Deal
What specific biological target does the licensed RNAi candidate address?
The candidate targets activin receptor-like kinase 7 (ALK7), a genetically validated target for obesity and metabolic diseases that is predominantly expressed in adipose tissue, according to Rona Therapeutics.
How much is the total potential value of the licensing agreement?
The agreement is valued at up to $1.16 billion, which includes a $100 million upfront payment and up to $1.06 billion in potential milestone payments, live reported.
When was Rona Therapeutics founded, and what is its core technology?
Founded in 2021, Rona Therapeutics develops RNA interference therapies utilizing a proprietary platform focused on extrahepatic delivery, multi-valency, and novel oligonucleotide chemistry, the company stated.